Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Brigham and Women's Hospital, Boston, MA, United States

Survival: 6.5 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Boston, MA
Hospital: Brigham and Women's Hospital
Journal: Link
Date: 9/2007

Patients: This phase II study involved 166 patients with progressive or recurrent advanced stage (IIIB or IV) non-small-cell lung cancer. All had received prior chemotherapy treatment. They ranged in age from 24-85 years old.

Treatment: All patients received the chemotherapy drug CI-1033. This drug is similar in action to erlotinib and gefitinib, in that it acts as a tyrosine kinase inhibitor. The patients were divided into three groups, and all received different doses of CI-1033.

Toxicity: One patient died from and adverse event, pneumonitis. The most common grade 4 toxicities included diarrhea, rash, nausea, asthenia, dyspnea, pain, and vomiting. These were more common in patients receiving the highest drug dose.

Results: The median overall survival was 196 days (6.4 months), 197 days (6.5 months) and 180 days (5.9 months) for patients receiving the low, medium, and high drug doses, respectively.

Support: Researchers involved in this study were supported by funds from Pfizer, Genentech, OSI Pharmaceuticals, and AstraZeneca. CI-1033 was developed by Pfizer.

Correspondence: Dr. Pasi A. Janne

E-mail to a Friend Email Physician More Information